The purpose of this study was to evaluate quality of life
(QOL), psychological function, and self-efficacy outcomes in the Anti-Arrhythmic Effects of Exercise
After an ICD Trial.
In the Anti-Arrhythmic Effects of Exercise
After an ICD Trial, 160 patients (124 men and 36 women) who had an implantable cardioverter defibrillator
for primary (43%) or secondary (57%) prevention were randomized to exercise
(EX, n = 84) or usual care (UC, n = 76). The EX consisted of 8 wk of home walking 1 hr/d 5 d/wk, followed by 16 wk of maintenance home walking for 150 min/wk. Adherence was determined from exercise
logs, ambulatory HR recordings, and phone calls. Assessments were conducted at baseline, 8, and 24 wk for QOL: Patient Concerns Assessment and Short Form-36; anxiety
: State Trait Anxiety
: Physician Health Questionnaire-Depression
; and self-efficacy: Self-Efficacy for Walking Scale.
Participants averaged 55 ± 12 yr of age with ejection fraction = 40.6 ± 15.7%. The EX significantly decreased depression
severity (EX: 1.33 ± 0.64; UC: 1.51 ± 0.86, P
= .05) and improved self-efficacy (EX: 7.65 ± 1.97; UC: 6.85 ± 2.40, P
= .05) at 8 wk. There were no significant effects at 24 wk. Adherent exercisers had significant improvements in QOL, psychological, and self-efficacy outcomes at 8 and 24 wk compared with those who were nonadherent. There were no implantable cardioverter defibrillator
shocks associated with exercise
The EX conferred significant effects on depression
and self-efficacy at 8 wk, without effects on QOL. Adherent exercisers experienced significant improvements in outcomes over those who were nonadherent or received UC.